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PseudovirionsPuumala (PUUV) and Hantaan (HTNV) viruses are hantaviruses within the family Bunyaviridae and associat-
ed with Hemorrhagic Fever with Renal Syndrome (HFRS) in humans. Little is known about how these viruses
interact with host cells, though pathogenic hantaviruses interact with αvβ3 integrin. To study host cell inter-
actions and rapidly test the ability of antibodies to prevent infection, we produced HTNV and PUUV pseudo-
virions on a vesicular stomatitis virus (VSV) core. Similar to replication-competent hantaviruses, infection
was low-pH-dependent. Despite broad cell tropism, several human T cell lines were poorly permissive to
hantavirus pseudovirions, compared to VSV, indicating a relative block to infection at the level of entry. Stable
expression of αvβ3 integrin in SupT1 cells did not restore infectivity. Finally, the pseudovirion system provid-
ed a rapid, quantitative, and speciﬁc method to screen for neutralizing antibodies in immune sera.A Johnson Pavilion, University
215 898 9557.
oms).
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Hantaviruses are negative-strand RNA viruses that are a genus
within the family Bunyaviridae. Unlike most bunyaviruses that are
carried and propagated via arthropods, transmission of hantaviruses
to humans is thought to occur through inhalation of aerosolized ro-
dent excreta (Tsai, 1987) and can result in two pathogenic and some-
times fatal diseases, Hemorrhagic Fever with Renal Syndrome (HFRS)
and Hantavirus Pulmonary Syndrome (HPS) (Hammerbeck and Jay,
2010). At this time, no safe and effective vaccines have been ap-
proved. In clinical trials, the antiviral drug ribavirin was somewhat ef-
fective against HFRS if used early after onset; however, ribavirin was
not effective against HPS probably because the duration from ﬁrst
symptoms to lethal disease is less for HPS (Huggins et al., 1991;
Mertz et al., 2004). Therefore, early diagnosis and support are cur-
rently the most effective means of treating these diseases (reviewed
in (Maes et al., 2009)).
Hantaviruses have anegative, single-strandRNAgenome that consists
of three segments, S, L, and M, which encode the nucleocapsid protein,
RNA polymerase, and the precursor to the virion envelope glycoproteins,
respectively. The glycoprotein precursor is co-translationally cleaved
to generate the glycoproteins GN and GC, which form heterodimers in
the endoplasmic reticulum (Deyde et al., 2005; Lober et al., 2001; Shiand Elliott, 2002). The speciﬁc roles of GN and GC in virus attachment
and entry are uncertain, though several studies suggest that GC functions
as a type-II membrane fusion protein (Cifuentes-Munoz et al., 2011;
Garry and Garry, 2004; Tischler et al., 2005).With regards to attachment,
a number of pathogenic hantaviruses have been shown to interact with
β3 integrin receptors on human endothelial cells (Gavrilovskaya et al.,
1998, 1999). Whether binding to β3 integrins results in endocytosis is
not clear, and whether other host cell molecules participate in virus
entry is not known. However, the broad tropism of hantaviruses in
vitro suggests that other cell surface molecules participate in virus infec-
tion, given the more limited expression of β3 integrins.
To facilitate the study of hantavirus interactions with host cells as
well as to rapidly and quantitatively test the ability of antibodies and
small molecules to prevent hantavirus infection, we developed an ef-
ﬁcient pseudovirion system in which the glycoproteins of Hantaan
(HTNV) or Puumala (PUUV) were placed on a vesicular stomatitis
virus (VSV) core carrying a reporter gene. The resulting pseudovirions
made it possible to reproducibly quantify virus infection within 24 h.
As has been observed for replication-competent hantaviruses (Jin
et al., 2002), the HTNV and PUUV pseudovirions required mildly acid-
ic pH for infection and were rapidly inactivated when incubated at or
below pH 6.0 in the absence of target cells. HTNV and PUUV pseudo-
virions infected a wide variety of cell lines in vitro, though several
human hematopoietic cell lines were very poorly permissive for
virus entry. Stable expression of the αvβ3 integrin heterodimer in
SupT1 cells did not rescue virus infection, and both HTNV and PUUV
pseudovirions could efﬁciently infect other cell lines lacking
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Fig. 1. Hantaan and Puumala pseudovirion infection and neutralization. Pseudovirions
containing HTNV, PUUV, or VSV glycoproteins were serially diluted before incubation
with Vero E6 cells. Infection after 24 h was measured by luciferase expression and
recorded as relative light units (RLUs) (A). Pseudovirions were incubated with anti-
bodies to VSV, HTNV, or PUUV glycoproteins prior to infection of Vero E6 cells. Percent
infection was determined compared to infection of each pseudovirion in the absence of
antibody pre-treatment. Neutralizations not tested are indicated with an asterisk (*)
(B).
135M.M. Higa et al. / Virology 423 (2012) 134–142detectable αvβ3 expression. Thus, αvβ3 expression was not sufﬁcient
to overcome the block to virus entry in SupT1 cells, suggesting that
additional host cell molecules are needed to support virus entry in
at least some cell types.
Results
Pseudovirion production
Hantaan (HTNV) and Puumala (PUUV) pseudovirions were pre-
pared similarly to previously described methods utilizing a vesicular
stomatitis virus (VSV) vector expressing either the Renilla luciferase
(rLuc) or red ﬂuorescent protein (RFP) genes (Ray et al., 2010). At-
tempts to produce HTNV or PUUV pseudovirions with retroviral sys-
tems were not successful (data not shown). VSV pseudovirions with
the VSV G gene provided in trans were used to transduce HEK 293T
cells that had been transfected with plasmids expressing either the
HTNV or PUUV M segments, of which PUUV-M was codon-optimized
for optimal translation in human cells. After transduction, cells were
incubated for 24–48 h at 37 °C and pseudovirion-containing media
was collected, ﬁltered, and the pH adjusted to 8.0. In some cases, pseu-
dovirions were concentrated through a sucrose cushion, resuspended
in TNE buffer, and frozen in aliquots. Pseudovirions were stable after
freezing, and could be freeze-thawed up to eight times without a sig-
niﬁcant loss in infectivity (data not shown).
Quantiﬁcation and titration of pseudovirions
Pseudovirion particle concentrations were determined by harvest-
ing viral RNA, reverse-transcribing RNA to cDNA, and measuring DNA
copies via real-time PCR ampliﬁcation. This quantitative PCR assay
was highly reproducible and linear over a ﬁve-log range, though it
provided only relative genome copies/μL due to the fact that we
used a plasmid control and so could not assess the efﬁciency of the
RT-PCR reaction. Nonetheless, the reproducibility and linearity of
this assay made it possible to normalize our virus stocks, and doing
so we found that all pseudovirions were produced at similar levels,
averaging 1–3×106 relative genome copies per mL regardless of the
viral protein or reporter gene being used. To measure viral infectivity,
we infected Vero E6 cells with HTNV, PUUV or VSV G pseudovirions
expressing either luciferase or RFP over a broad concentration range
and quantiﬁed infection either by relative light units (RLUs) or by
percent RFP-expressing cells by ﬂow cytometry. Using VSV M anti-
body (23H12) staining to measure the number of infected cells by
FACS for both reporters, we found that 109 infectious VSV G pseudo-
virions were produced per mL of media, while infectious PUUV and
HTNV pseudovirions were produced at levels two-logs lower despite
similar levels of particle production (between 106 and 107 relative
genome copies per mL). Thus, the PUUV and HTNV pseudovirions
were approximately 100-fold less infectious than VSV G pseudovir-
ions on a per-particle basis. rLuc detection by luminometry was
both more sensitive and higher-throughput than assessing infection
via FACS analysis, and thus this detection method was used for most
experiments. To conﬁrm that rLuc pseudovirion infection yielded sig-
nal in the linear range, cells were infected with 2-fold dilutions of
pseudovirions for 24 h before cell lysis and measurement by lumin-
ometer (Fig. 1A). Subsequent experiments were done at pseudovirion
dilutions that resulted in RLUs between 100 and 1000 (5–200 relative
genome copies) in Vero E6 cells, well within the linear range of the
detection.
Glycoprotein-speciﬁc antibodies neutralize pseudovirion infection
To verify that infectivity was facilitated by HTNV or PUUV glyco-
proteins and not by residual VSV G protein, pseudovirions were pre-
treated with either a mouse monoclonal antibody raised againstHTNV GC (11E10), PUUV-M monkey antisera (A15089), or with a
neutralizing VSV G-speciﬁc antibody (I14). Infection of Vero E6 cells
was reduced by approximately three-logs when PUUV and HTNV
pseudovirions were pre-treated with their respective immune sera
or monoclonal antibody whereas VSV pseudovirions were not affect-
ed (Fig. 1B). In contrast, VSV but not HTNV or PUUV pseudovirions
were neutralized after pre-treatment with the anti-VSV Gmonoclonal
antibody, I14. Thus, pseudovirion infection was mediated by the ap-
propriate glycoproteins.
Pseudovirion cell entry is pH-dependent
Aswith othermembers of the familyBunyaviridae, cells infectedwith
hantaviruses form syncytia under acidic pH conditions (McCaughey et
al., 1999; Ogino et al., 2004) and the glycoproteins were determined to
be the fusogens (Ogino et al., 2004; Zheng et al., 2007). To determine
whether PUUV and HTNV pseudovirion infection was also dependent
upon low pH, we treated cells with two lysosomotropic agents, ammo-
nium chloride (NH4Cl) and chloroquine. Both agents inhibit acidiﬁcation
of intracellular compartments, though by differentmechanisms. In addi-
tion to PUUV and HTNV pseudovirions, we also prepared and infected
cells with Nipah Virus (NiV) pseudovirions. NiV (of the family Paramyx-
oviridae) entry is pH-independent (Moll et al., 2004; Tamin et al., 2002),
so its infection is unaffected by lysosomotropic agents. Vero E6 cells
were pre-treated for 30 min with increasing concentrations of NH4Cl
(Fig. 2A) or chloroquine (Fig. 2B). Pseudovirions were then added
and infection was allowed to occur for 24 h before luciferase expres-
sionwas analyzed. Both HTNV and PUUV pseudovirion infectionwas re-
duced with increasing concentrations of NH4Cl and chloroquine. In
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Fig. 2. Requirement of low-pH in infection of cells with hantavirus pseudovirions. Vero
E6 cells were pre-incubated with increasing concentrations of NH4Cl (A) or Chloro-
quine (B), prior to infection with Nipah (NiV), Puumala (PUUV), or Hantaan (HTNV)
pseudovirions. VSV, NiV, PUUV, and HTNV pseudovirions were exposed to pH ranging
from 4.5 to 7.4 in the absence of membranes for 30 min. Pseudovirions were back-
neutralized and used to infect Vero E6 cells (C).
136 M.M. Higa et al. / Virology 423 (2012) 134–142contrast, pH-independent NiV pseudovirions maintained consistent
levels of infection at all NH4Cl and chloroquine concentrations tested, in-
dicating that these compounds did not affect post-entry steps. Taken to-
gether, this low pH-dependent infection suggests that productive
hantavirus pseudovirion involves virus internalization and delivery to
an acidic organelle as has been reported for HTNV previously (Jin et al.,
2002).Pretreatment with acidic pH inactivates PUUV and HTNV infections
Bunyavirus entry requires both glycoproteins GN and GC, although
the individual roles of each glycoprotein in binding, fusion, and entry
have yet to be fully elucidated. Several groups have suggested that the
GC glycoprotein contains a fusion peptide and is similar in structure toclass II viral fusion proteins (Garry and Garry, 2004; Tischler et al.,
2005). One characteristic of some class II viral fusion proteins is that
they undergo irreversible conformational changes upon exposure to
low pH (reviewed in (Earp et al., 2005; Kielian, 2006)). In the absence
of cell membranes, such changes can render viruses inactive. To de-
termine if hantavirus pseudovirions are also inactivated upon expo-
sure to low pH, we pre-incubated pseudovirions in buffer ranging in
pH from 4.5 to 7.4 for 30 min and then returned them to neutral pH
(~pH 7.2–7.4) before applying them to Vero E6 cells for infection
(Fig. 2C). In parallel, NiV and VSV G pseudovirions were also sub-
jected to the same pH treatment prior to infection. NiV entry is pH-
independent, while the G protein of VSV is unusual in that it un-
dergoes reversible changes at low pH (Puri et al., 1988). We found
that when HTNV or PUUV pseudovirions were incubated at pH values
below 6.0 prior to pH neutralization and infection, there was a
marked decrease in infection, with the midpoint of inactivation
being approximately pH 6.2. In contrast, both NiV and VSV G pseudo-
virions were still able to infect cells when exposed to the same
pH pre-treatments. These data are consistent with low pH triggering
irreversible conformational changes in the HTNV and PUUV glycopro-
teins that lead to infection when virus is bound to a cell, or inactiva-
tion in the absence of a target membrane.
Hantavirus pseudovirions exhibit broad cell tropism
Based on analysis of human and rodent pathology specimens aswell
as assays with cultured cells, hantaviruses have been shown to have
wide tissue tropism. In pathology specimens, virus antigens have been
detected in endothelial cells throughout the body, including lung endo-
thelial cells for infections associated with HPS or kidney endothelial
cells in cases where HFRS was the associated disease (Hung et al.,
1992; Netski et al., 1999; Zaki et al., 1995). In addition, serologic surveys
have identiﬁed hantavirus antigens in a range of mammals, indicating
that these viruses are capable of infecting many mammalian hosts
(reviewed in (Ulrich et al., 2002)). To examine the cellular tropism of
the PUUV and HTNV pseudovirions, we infected cell lines derived
from different tissues and species. Cells were infected with PUUV and
HTNV pseudovirions, and luciferase production measured 24 h later
(Fig. 3). In each experiment, Vero E6 cells were included as a positive
control. In addition, to control for post-entry differences in replication,
VSV G pseudovirions were also included in all infections. Cells were
infected with virus dilutions well within the linear range of the assay
and empirically determined to give similar levels of infection on Vero
E6 cells. In this way, we could identify cells differentially susceptible
to infection by any given virus. Of the cell lines tested, only a few
were non-permissive to all pseudovirions tested (the iguana cell line
IGH2 and data not shown), indicating an inability to support pseudovir-
ion replication. The majority was readily susceptible to infection by all
pseudovirions at levels of N50% compared to infection of Vero E6 cells
(Fig. 3 and Table 1). Interestingly, while the human T cell lines SupT1
and MOLT4 supported efﬁcient infection by VSV pseudovirions, infec-
tion by PUUV or HTNV pseudovirions was approximately three logs-
less efﬁcient. Though less pronounced, the T cell lines, CEMx174 and
HUT, also showed a marked difference in infectivity between VSV and
hantavirus pseudovirions. Since infection by VSV G pseudovirions was
efﬁcient, the failure of HTNV and PUUV pseudovirions to infect SupT1
andMOLT4 cells is likely due to a block at the level of virus entry. To de-
termine if the low luciferase expression by HTNV and PUUV pseudovir-
ions in these T cell lines was due to a small sub-population of cells that
were infected efﬁciently or low level luciferase production in a larger
number of cells, we used RFP-expressing pseudovirions to infect
SupT1 cells and measured infectivity by ﬂow cytometry. While only
0.2% of SupT1 cells were infected by RFP-expressing hantavirus pseudo-
virions, the cells thatwere infected expressed RFP at a high level. In con-
trast, 29% of SupT1 cells were infected with RFP-expressing VSV
pseudovirions, similar to what had been seen with luciferase-
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Fig. 3. Cell tropism of pseudovirions. A variety of cell lines from different tissues and organisms were infected with VSV, HTNV, or PUUV pseudovirions and luciferase measured after
24 h. Infection was measured as a percentage of the ability of each pseudovirion to infect Vero E6 cells, as determined by RLUs. Bars indicate the average of multiple (at least 3)
experiments performed in triplicate +/− SD.
137M.M. Higa et al. / Virology 423 (2012) 134–142expressing VSV pseudovirions (data not shown). Because cell lines can
be genetically variable, we sought to determine whether the infected
cells were part of a heterogeneous population of cells that could beTable 1
Pseudotype cell tropism.
Cell lines Species Tissue type Pseudotypes αvβ3
expression
VSV HTNV PUUV GMFI STDEV
Vero E6 African
green
monkey
Kidney ++
+
++
+
++
+
160.05 65.07
K562a Human Bone marrow
erythroleukemia
+ +/− + 1.29 0.58
HEL
92.1.7a
Human Bone marrow
erythroleukemia
+ + ++ 17.10 14.79
SupT1a Human Non-Hodgkins
T-cell
lymphoma
+ – – 1.65 1.21
CEMx174a Human Precursor B-
lymphoid
+/
−
– – 2.94 1.41
MOLTa Human Acute
lymphoblast
leukemia
++ – - 1.68 0.34
HUTa Human Cutaneous T
lymphocyte
+/
−
– - 0.33 0.16
293T Human Kidney ++
++
+ ++
++
0.67 0.05
MRC5 Human Lung ++ + ++
++
7.03 1.71
HHL5 Human Liver + +/− + 178.27 40.83
HeLa Human Cervix + + ++ 17.30 6.67
HeLa S3 Human Cervix,
suspension
+ + ++
+
0.55 0.58
3 T3 Mouse Embryo + +/− + 0.17 0.11
QT6 Japanese
Quail
Fibrosarcoma ++
+
+ ++
+
1.57 0.06
CF2TH Dog Thymus ++
+
+ ++
+
85.57 57.88
IGH2 Iguana Heart – – – 1.20 1.27
Key
% Infection Score
N150% ++++
100–150 +++
50–100 ++
10–50 +
1–10 +/−
0.1–1 -
0.001–0.1 –
a Indicates hematopoetic cell line.selected against. SupT1 cells were infected with high concentrations
of hantavirus RFP pseudovirions tomaximally infect and kill permissive
cells. This was repeated inmultiple rounds after allowing surviving cells
to expand before re-infection. After each infection, the percentage of
infected cells was measured by ﬂow cytometry. RFP-positive cells
remained low but relatively constant between rounds of infection
(data not shown). This ﬁnding suggests that SupT1 cells are poorly per-
missive to virus entry, and that infected cells do not represent a sub-
population of highly permissive cells.
Cell tropism does not correlate with cell surface αvβ3 integrin expression
It has been reported previously that pathogenic HPS- and HFRS-
causing hantaviruses enter cells viaαvβ3 integrin heterodimers (Gavri-
lovskaya et al., 1998, 1999) due to interactions between hantavirus gly-
coproteins and the plexin-semaphorin-integrin (PSI) domain of β3
integrin subunits (Matthys et al., 2010; Raymond et al., 2005). We
therefore sought to determine whether cell tropism correlated with
the presence or absence of αvβ3 integrin on the surface of cells. We
looked at the αvβ3 integrin surface expression of most of the cell lines
tested, including ones that were very permissive (293T), permissive
(Vero E6), or poorly permissive (SupT1) to infection by HTNV and
PUUV pseudovirions. Each cell type was incubated with ﬂuorescently
conjugated antibodies that recognized the αvβ3 heterodimer. We ana-
lyzed surface expression by ﬂow cytometry and determined geometric
mean ﬂuorescence intensities (GMFI) for each cell line (Table 1). Using
an anti-human αvβ3 antibody, we were able to detect surface expres-
sion on human, monkey, and dog cells. These cell types showed no cor-
relation between αvβ3 surface expression and PUUV (p=0.8725) or
HTNV (p=0.1809) pseudotype infection. For Vero E6, 293T, and
SupT1 cell lines, we measured surface expression of the β3 integrin
alone, as well as theαvβ3 heterodimer. Vero E6 cells, which are permis-
sive to HTNV and PUUV pseudotype infection, showed strong surface
expression of both β3 integrin and the αvβ3 heterodimer, as indicated
by a GMFI of 160 and an increase of ~2.5 log ﬂuorescence (Table 1;
Fig. 4A). In contrast, poorly permissive SupT1 cells did not show an in-
crease in surface expression of the integrin (1.645 GMFI). Somewhat
surprisingly, 293T cells, which were very permissive to infection,
showed background levels of ﬂuorescence (0.665 GMFI) suggesting
that there was little to no expression of β3 integrin on the cell surface
(Table 1; Fig. 4A). We next sought to determine if over-expression of
αvβ3 integrins in SupT1 cells could rescue infection. After stably nucleo-
fecting SupT1 cells with αv and β3 expression plasmids, the αvβ3 het-
erodimer was expressed in 95% of cells compared to b1% in non-
nucleofected cells, as determined by ﬂow cytometry (Fig. 4B). Integrin
αvβ3- expressing and non-expressing SupT1 cells were then infected
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Fig. 4. Surface staining of αvβ3 on cells with varying permissivity to hantavirus pseudovirion infection. Endogenous surface expression of integrin β3 alone (green line), the hetero-
dimer αvβ3 (blue line), or intracellular ERK (red line) as a control, was measured by ﬂow cytometry using PE-conjugated antibodies. Integrin expression in SupT1, 293T, and Vero E6
cells was measured (A). SupT1 cells were nucleofected with plasmids expressing αv and β3 integrins and selected with G418 to create a SupT1 αvβ3 stable cell line. Expression of
αvβ3 in nucleofected (dark gray, shaded), non-nucleofected cells (black line), or Vero E6 cells (light gray, shaded) was detected using a PE-conjugated anti-αvβ3 antibody and an-
alyzed by ﬂow cytometry (B). Wild-type (top row) and stably-nucleofected (bottom row) SupT1 cells were either not infected, or infected with equal genome copies of HTNV,
PUUV, or VSV pseudovirions. Integrin αvβ3 surface expression and pseudovirion infection were detected by PE-conjugated anti-αvβ3 antibody (y-axis) and mAb VSV M (x-axis),
respectively, and analyzed by ﬂow cytometry (C).
138 M.M. Higa et al. / Virology 423 (2012) 134–142with VSV, HTNV, and PUUV pseudovirions. We found that expression of
theαvβ3 heterodimer on SupT1 cells did not increase infection byHTNV
or PUUVpseudovirions, while VSV pseudovirion infection of SupT1 cells
was not signiﬁcantly affected by αvβ3 expression (Fig. 4C).
Non-human mammal anti-sera neutralize hantavirus pseudovirions at
titers comparable to PRNT assays
DNA vaccines that express the GN and GC glycoproteins of hantavi-
ruses can elicit neutralizing antibodies against these proteins and can
confer protection against infection in Syrian hamsters (Custer et al.,
2003; Hooper et al., 1999, 2001, 2006, 2008). Besides animal challenge
with virus, the plaque reduction neutralization test (PRNT) is common-
ly used to quantify hantavirus neutralizing antibodies. This assay takes
several weeks to complete, is expensive to run, and for some hantavi-
ruses requires high containment facilities. Therefore, there is a need
for a rapid, sensitive, and safe method to assess hantavirus neutraliza-
tion activity in sera. In contrast to the PRNT assay, pseudovirion assays
are completed in b3 days, require relatively small amounts of material,
and are amenable to biosafety level 2 (BSL2) conditions.
To determine if pseudovirions could also be neutralized by sera
fromDNA-vaccinated animals, we blind-tested 72 hamster or monkey
sera samples (25 pre-immune sera, 24 HTNV sera, and 23 PUUV sera)
for neutralizing activity against PUUV and HTNV pseudovirions. These
sera were previously screened for virus neutralization titers by PRNTon Vero E6 cells (Hooper, in preparation; Hooper et al., 2001, 2006;
Jonsson et al., 2008). Pseudovirions were pre-incubated with 2-fold
dilutions of sera prior to infecting Vero E6 cells and IC50 values calcu-
lated from the resulting neutralization curves. Representative sera ti-
trations are shown in Fig. 5 and their corresponding IC50 and PRNT
values reported in Tables 2 and S2 (Supplementary material). We
completed full titrations in duplicate for all pre-immune sera as
well as 20 HTNV sera and 19 PUUV sera. Limited volumes for some
sera prevented us from completing full titrations for all samples
(Table S2; N/A). As expected, pre-immune sera were not able to neu-
tralize HTNV or PUUV pseudovirions; at the highest sera concentra-
tion (1:25 dilution), average percent infection of HTNV and PUUV
pseudovirions was 102.53±19.36% and 77.8±21.47%, respectively
(data not shown). Twenty HTNV sera and 23 PUUV sera were able to
neutralize infection of the respective pseudovirion by at least 50%; 6
HTNV sera and 13 PUUV sera reduced pseudovirion infection 80% or
more (Table S2). Cross-neutralization activity of sera from both
HTNV- and PUUV- vaccinated animals did not exceed 32% or 37%, re-
spectively, indicating that neutralizationwas speciﬁc for the glycopro-
tein vaccinated against (data not shown). Pseudovirion neutralization
IC50 titers ranged from 50 to 989 for PUUV and 33–23,980 for HTNV.
The respective geometric mean titers (GMTs) were 230 for PUUV
and 274 for HTNV. In contrast, PRNT50 titers ranged from 28 to
5120 for PUUV and 28–40,960 for HTNV, with respective GMTs of
266 (PUUV) and 765 (HTNV). These data show that neutralizing
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Fig. 5. Antisera from DNA-vaccinated monkeys or hamsters was serially diluted (1:50–
1:40,000) and incubated with HTNV (A) or PUUV (B) pseudovirions, prior to infecting
Vero E6 cells. Infection was measured by Renilla luciferase expression, and graphed as a
percentage of infection in the absence of antisera. Symbols represent the mean +/− SD
of duplicates.
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dovirions system at titers comparable to those used in PRNT assays.
Discussion
Several previous studies have demonstrated that hantavirus gly-
coproteins can be pseudotyped onto VSV (Ogino et al., 2003) and len-
tiviral (Cifuentes-Munoz et al., 2010) vectors. Such systems present aTable 2
IC50 values of PUUV and HTNV sera neutralization.
Animal ID Ψ IC50 R2 PRNT50 Species
PUUV sera
241 989 0.9421 5120 Hamster
261 628 0.9285 905 Hamster
A16693 224 0.9094 160 Monkey
248 150 0.9081 2560 Hamster
212 60 0.9026 320 Hamster
246 57 0.2737 b20 Hamster
HTNV sera
CH28a 3699 0.9445 20,480 Monkey
259 883 0.8327 905 Hamster
253 206 0.6538 57 Hamster
CH85b 132 0.7619 1280 Monkey
187 113 0.5276 113 Hamster
235 65 0.4356 1280 Hamster
a Indicates PRNT IC50 data was previously published and is re-stated here for com-
parison purposes (Fig. 2D in Hooper et al., 2006).
b Indicates PRNT IC50 data was previously published and is re-stated here for com-
parison purposes (Fig. 3C in Custer et al., 2003).safe and effective method for studying virus entry, as they are pro-
duced at reasonable titers and require only BSL2 conditions. We opti-
mized a system whereby PUUV and HTNV glycoproteins are
pseudotyped onto a VSV core expressing a reporter gene, and
obtained pseudovirions at titers of approximately 106 I.U./mL for
HTNV and PUUV, and 108 I.U./mL for VSV G which is similar to what
others have reported with Andes (Cifuentes-Munoz et al., 2010),
HTNV, and Seoul Viruses (Ogino et al., 2003). Despite the 2-log differ-
ence between hantavirus and VSV G infectious units, genome copies
of all pseudovirions were present at comparable levels, indicating
that the hantavirus pseudovirions were considerably less infectious
on a per-particle basis relative to VSV G pseudovirions. This discrep-
ancy could be due to more efﬁcient incorporation of the VSV glyco-
protein onto its own core, or enhanced stability or fusogenicity of
VSV G. Indeed, an inherent assembly and budding activity is associat-
ed with the VSV glycoprotein itself (Robison andWhitt, 2000; Rolls et
al., 1994). Pseudovirion structure may also contribute to differences
in infectious particles. Recent cryo-electron studies of hantaviruses
indicate that the majority of virions are spherical and exhibit a 4-
fold symmetric lattice of GN–GC spikes (Battisti et al., 2011; Huisko-
nen et al., 2010). In contrast, the VSV core is bullet-shaped and VSV
glycoproteins are displayed on the viral envelope as trimers (Doms
et al., 1987). Therefore, pseudotyping hantavirus glycoproteins onto
a VSV core could alter GN–GC oligomerization or their interactions
with host membranes, resulting in less infectious particles.
While the HTNV and PUUV pseudovirions developed here were less
infectious than particles bearing the native VSV G glycoprotein, they
nonetheless recapitulated two cardinal features of the native virions—
very broad cellular tropism and a requirement for low pH. Viruses that
require low pH to fuse to target membranes can enter cells by different
endocytic routes. Ahn and colleagues (Jin et al., 2002) showed that chlor-
promazine and hypertonicity signiﬁcantly reduced infection of cells with
HTNV, suggesting that entry is mediated by clathrin-dependent
receptor-mediated endocytosis. Consistent with this, conformational
changes at ~pH 6.0–6.4 have been seen with bunyavirus glycoproteins
from the sub-genera Orthobunyavirus (La Crosse Virus; (Pekosz and
Gonzalez-Scarano, 1996)), Phlebovirus (Uukuniemi Virus; (Overby
et al., 2008)) and recently with Hantavirus (PUUV and Tula viruses
[TULV]; (Hepojoki et al., 2010)).
Based on structural modeling, hantavirus Gc is thought to be a class II
fusion protein (Tischler et al., 2005), and some class II fusion proteins un-
dergo irreversible conformational changeswhenexposed to lowpH (Earp
et al., 2005). Likewise, we found that exposure of PUUV and HTNV pseu-
dovirions to a pHof 6.0–6.2 in the absence ofmembranes resulted in rapid
inactivation, even after return to neutral pH. Though this is consistent
with at least some aspects of the lowpH-induced conformational changes
being functionally irreversible,whether this is the case for all hantaviruses
has not been deﬁnitively determined. Recently it was proposed that the
hantaviruses PUUVandTULVundergo a pH-reversible fusionprocess. Lan-
kinen and colleagues found that low pH-dissociated PUUV glycoproteins
could be co-immunoprecipitated after back-neutralization to pH 8.0
(Hepojoki et al., 2010). They also observed a 1% residual infection after
pH-inactivating TULV, which they attributed to reversible conformational
changes. This discrepancymight be explained by an initial pH-dependent
dissociation of GN and GC that is reversible, similar to what has been
reported for other class II fusion proteins (Allison et al., 1995; Yu et al.,
2008). However, since a return to neutral pH for both TULV and our pseu-
dovirions did not rescue infectivity in the presence of membranes, this
suggests that later fusion steps are irreversible. The residual infection
could be due to a second, much less efﬁcient non pH-dependent entry
mechanism, or a subset of virus thatwas shielded fromacidic inactivation.
Viruses in the Bunyaviridae family, in general, exhibit a broad cellular
tropism in vitro. Consistent with this, we found that PUUV and HTNV
pseudovirions were able to infect cell lines from a range of organisms
and tissue types. However, infection of several human T cell lines by
PUUV or HTNV pseudovirions was 2–3 logs less than the levels of
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infection at the level of entry (Fig. 3; Table 1). Since the integrin αvβ3
has been implicated as a receptor for pathogenic hantaviruses, such as
PUUV and HTNV (Gavrilovskaya et al., 1998, 1999), we analyzed surface
expression of this integrin heterodimer in several cell types. Interestingly,
we found that the expression ofαvβ3 did not correlate with viral infectiv-
ity—293T cells were readily infected despite having no or very low levels
of αvβ3, while SupT1 cells were very poorly permissive to infection even
when caused to over-expressαvβ3 integrin (Fig. 4). These results suggest
that the presence ofαvβ3 on SupT1 cells is not sufﬁcient to allow entry of
the VSV core. The marked reduction in the ability of HTNV and PUUV
pseudovirions to enter SupT1 and other human T cell lines raises the pos-
sibility that hantavirus entry requires additional cellular factors that are
not present in these cell lines. Consistent with this, (Krautkramer and
Zeier, 2008) have reported that hantavirus causing HFRS require decay
accelerating factor (DAF/CD55) as a co-receptor and Bai and colleagues
showed that HTNA9 directly interacts with β3 integrins aswell as an uni-
dentiﬁed 70 kDa protein (Mou et al., 2006).
Currently, hantavirus neutralization assays are relatively time-
consuming and require the use of replication-competent viruses in
high-containment (BSL3 or BSL4) facilities. As pseudovirions can be pro-
duced in high quantities, require only BSL2 conditions, and are amenable
to high-throughput analysis, they provide an attractive alternative to test
sera for the presence of neutralizing antibodies.We found that hantavirus
pseudovirions, but not VSV G, were neutralized by sera from animals vac-
cinated with hantavirus M segment-based plasmid DNA vaccines, and at
titers similar to those used for PRNT assays (Fig. 5; Table 2). The pseudo-
virion neutralization assay was highly reproducible, sensitive, and specif-
ic, making it possible to calculate IC50 values. However, there were some
discrepancies between the pseudovirion and PRNT assays, somore exten-
sive testing will be required to compare and contrast these two
approaches.
In summary, we have begun to optimize a pseudovirion system for
rapidly and effectively detecting hantavirus neutralizing antibodies,
which could potentially be used as a safer alternative to existing diagnos-
tic assays. Hantavirus glycoprotein-expressing pseudovirions infect cells
in a pH-dependent manner, and are neutralized by antibodies speciﬁc
to their glycoproteins. In addition, these pseudovirions exhibit broad cell
tropism. The relationship between infection andαvβ3 integrin expression
in certain cell types appears to be complicated, as some cells with little
αvβ3 expression exhibit robust infection, while infection of other cells
cannot be recovered by increased expression of αvβ3 integrin. Taken to-
gether, hantavirus pseudovirions are an effective and quantitative
means with which to investigate virus entry.Methods
Cells and reagents
Vero E6, HEK 293T/17, HeLa, CF2TH, QT6, MRC5, HHL5, 3T3, and IGH2
cells were grown in Dulbecco's Modiﬁed Eagle Medium (DMEM) supple-
mented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), L-gluta-
mine, and penicillin–streptomycin (GIBCO). SupT1, K562, HEL 92.1.7,
CEMx174, HUT, and MOLT cells were grown in RPMI Medium 1640
(Gibco) supplemented with 10% fetal bovine serum and penicillin–strep-
tomycin. The VSVΔG*rLuc pseudovirion is a recombinant VSV derived
from a full-length cDNA clone of the VSV Indiana serotype in which the
G-protein gene has been replaced with the Renilla luciferase gene (Ray
et al., 2010). G-protein supplemented in trans resulted in single-round in-
fectious VSVΔG*rLuc virions as described below (Negrete et al., 2005).
Plasmids containing the M genome segments of HTNV and PUUV
(pWRG/HTN-M[x] and pWRG/PUU-M[s2], respectively) were described
previously (Hooper et al., 2001). Anti-HTNV and anti-PUUV sera were
obtained from hamsters or monkeys vaccinated with DNA vaccines to
HTNV and PUUV as described previously (Hooper et al., 2001). Dr. DougLyles (Wake Forest University) kindly provided antibodies to VSV G
(I14) and VSV M (23H12) (Lefrancois and Lyles, 1982).
Preparation of HTNV, PUUV, and VSV pseudovirions
Pseudovirionswere preparedusing amodiﬁed version of a previous-
ly described method (Ogino et al., 2003; Takada et al., 1997). HEK293T
cells were seeded in 10-cm tissue culture plates and transfected with
plasmids expressing hantavirus M segments or VSV G protein using
Lipofectamine 2000 (LF2000, Invitrogen) at ~80% conﬂuency. After six
hours or overnight, transfection media was removed and replaced
with fresh media for approximately 12 h. Cells were then infected
with either VSVΔG*rLuc or VSVΔG*RFP at a multiplicity of infection
(MOI) of between 0.1 and 0.02 for one hour at 37 °C, after which the in-
oculumwas removed, cells washed three timeswithmedia and then in-
cubated at 37 °C for 24 h. Supernatant from infected cells was collected
and mixed with Tris pH 8.0 to a ﬁnal concentration of 20 mM. This su-
pernatant was then clariﬁed by low speed centrifugation and ﬁltration
through a 0.22 μm ﬁlter prior to aliquoting and storage at −80 °C. In
some cases, a more concentrated pseudovirion preparation was re-
quired. In these cases, after clariﬁcation and ﬁltration, pseudovirions
were concentrated at 40,000 rpm in a SW41 rotor for 1 h through a
20% sucrose cushion prepared in TNE buffer (10 mM Tris, 135 mM
NaCl, 2 mM EDTA, pH 8.0). The pellet was resuspended overnight in
500 μL TNE buffer, aliquoted and stored at−80 °C.
Quantiﬁcation of viral particles
To measure viral genome copies, four 3-fold dilutions of for each
virus stock in 100 μL PBS+/+ (Gibco C/N: 14040) were directly lysed
using 100 μL of Lysis/Binding Solution (Ambion 8540G5) from RNA-
queous©-96 Kit. Viral RNA was harvested using the Ambion RNAqu-
eous©-96 Kit (AM1920) and eluted in 50 μL nuclease-free water.
10 μL of eluted RNA was then reverse transcribed using Superscript
III from Invitrogen (CN: 18080-044) with 4 pmol of N62-forward
primer [CGGAGGATTGACGACTAATGC].
Quantitative PCRwas similar to that described previously (Coleman
et al., 2007). HPLC puriﬁed primers used to amplify a 62-bp fragment of
the VSV N gene (N62) were N62-forward (above) and N62-reverse
[ACCATCCGAGCCATTCGA]. Ampliﬁcation was quantiﬁed using a MGB
6-FAM™ probe [CGCCACAAGGCAG] from Applied Biosystems. Primers
and probe at 200 nM ﬁnal concentration were used with the 2×
TaqMan® Universal PCR Master Mix (Applied Biosystems P/N:
4304437) in a 20 μL reaction. Data collection and analysis was done
using the Applied Biosystems 7500 Fast Real-Time PCR system.
As a standard, a 445-nucleotide region (N445) of the VSV N gene
encompassing the N62 fragment was cloned into the pCR2.1 TOPO
vector. Plasmid was linearized with Hind III and quantiﬁed using the
Quant-iT™ dsDNA Assay Kit from Invitrogen (C/N: Q33120). To create
a standard curve, linearized plasmid was serially diluted and used for
qPCR analysis. A standard dilution curve from 101 to 106 copies/μL on
each plate was used to quantify unknown samples.
The amount of virus (μL) vs. concentration of ampliﬁed viral DNA
(copies/μL) was plotted and linear regression analysis was calculated
using GraphPad Prism® 4.0 software. The slope of the best-ﬁt line
was used as a constant to calculate DNA copies/μL (R2 values ranged
0.95–0.99). DNA concentration is not a direct measurement of viral
RNA concentration, but rather the DNA copies resulting after reverse
transcription. We found that this qPCR assay was highly reproducible,
giving essentially identical results when the same samples were ana-
lyzed on different days.
Quantiﬁcation of pseudovirion infection
In a typical infection, pseudovirions were diluted into PBS+1% FBS,
added to cells, and incubated at 37 °C for 1 h. An equal volume of media
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for 24 h. After 24 h, cellswere lysed and levels of luciferasemeasured on a
Luminoskan Ascent (Thermo Scientiﬁc) using the Renilla luciferase assay
system following the manufacturer's protocol (Promega). Alternatively,
cells were analyzed for red ﬂuorescent protein (RFP) expression by ﬂow
cytometry. For suspension cells, the cells were seeded at ~10,000 cells/
well in V-bottom plates. Following addition of pseudovirions, cells were
spinoculated for 1 h at 2000 rpm and incubated at 37 °C for 24 h.
Infectious units (I.U.)/μL were determined in several ways depending
on the virus used. For pseudovirions expressing luciferase, cells were har-
vested 24 h post-infection using 0.05% trypsin-EDTA from GIBCO (C/N
25300) and then ﬁxed and stained using BD Cytoﬁx/Cytoperm™ Fixa-
tion/Permeabilization Kit (C/N 554714). Brieﬂy, cells were resuspended
in 50 μL Fixation and Permeabilization Solution and incubated at 4 °C for
20 min. Cells were washed with 1 mL Perm/Wash Buffer and stained for
VSV matrix (M) protein using 23H12 antibody at 1:125 in 50 μL Perm/
Wash Buffer for 1 h at room temperature. After washing, Alexa Fluor®
680 donkey anti-mouse IgG (H+L) from Invitrogen (C/N A10038) was
used for secondary antibody staining at 1:1000 in 50 μL Perm/Wash Buff-
er for 1 h at room temperature. Cells werewashed twicewith FACS buffer
(PBS+/+, 1% BSA, 0.05% NaN3) and resuspended in 250 μL FACS buffer+
1% paraformaldehyde (PFA). Percent infection of cells was determined
by ﬂow cytometry.
pH dependency analysis
To determine the effect of pH on pseudovirion entry, pseudovirions
were diluted 10-foldwith Earle's salt solution (Invitrogen) supplemented
with 20 mMHEPES and 20 mMMES, and adjusted to the appropriate pH
for 15 min at 37 °C. pH-incubated pseudovirions were then neutralized
with warmed media and incubated at 37 °C for 15 min. After incubation,
100 μL pseudovirionswere added to Vero E6 cells in a 96-well format and
incubated at 37 °C for 1 h. Pseudovirionswere diluted two-fold by adding
100 μL media to each infected well and incubated at 37 °C for 24 h. Infec-
tion and luciferase expression were analyzed and detected as above.
Treatment with lysosomotropic agents
Vero E6 cells were pre-treated with NH4Cl or chloroquine (Sigma)
at the indicated concentrations before infection with pseudovirions.
The agents were added to cells at 0–200 μM for 30 min at 37 °C. The
buffer was removed and 100 μL pseudovirions diluted in 1× PBS
+1% FBS were added to cells. After 30 min at 37 °C, 100 μL media
was added to cells and they were incubated at 37 °C for 24 h. Infec-
tion and luciferase expression were analyzed and detected as above.
Stable nucleofection and infection of SupT1 cells
SupT1 cells were nucleofected according to protocol using the
Amaxa® Cell Line Nucleofector® Kit V (Lonza Cat. No. VCA-1003).
Two days post-nucleofection, media was replaced with selection
media containing geneticin (Invitrogen C/N 10131-035) at 400 μg/mL.
Cells were cultured in selection media for 25 days until a signiﬁcant
αvβ3 expressing population was measureable by ﬂow cytometry.
Wild-type and αvβ3-expressing SupT1 cells were in a 12-well plate at
5×105 cells/well with 3.6×105 copies/μL of HTNV, PUUV, and VSV
rLuc pseudovirions. After 1 h, the inoculum was diluted four-fold with
media.
Detection of VSV M, αv and β3 integrins by ﬂow cytometry
HEK293T, Vero E6, and SupT1 cells were washed with PBS, re-
moved with cell dissociation buffer (2 mM EDTA/PBS), and transferred
to V-bottom FACS tubes. Cells were washed with PBS/BSA, incubated
with 0.06 μg PE mouse anti-human CD61 (β3 integrin), PE mouse anti-
human CD51/61 (αvβ3 integrin) antibody, or PE mouse anti-ERK (as anisotype control) (BD Biosciences, material numbers 555754, 550037,
and 612566, respectively) in PBS/BSA at 4 °C for one hour. Cells were
then washed with PBS, transferred to FACS tubes and stained with
LIVE⁄DEAD® Fixable Aqua Dead Cell Stain Kit (Invitrogen C/N 34957).
Cells were washed with FACS buffer and ﬁxed/permeabilized either
with 1% PFA or BD Cytoﬁx/Cytoperm™ solution (BD C/N 51-2090KZ
(554722)). VSV M was detected after infection by staining with 23H12
anti VSV M antibody, then washed and stained with Alexa Fluor® 680
goat anti mouse IgG antibody (Invitrogen C/N A10038). Cells were
washedwith FACS buffer and ﬁxedwith 1% PFA in FACS buffer and stored
at 4 °C. Expression and infection were analyzed using a FACSCalibur or
LSRII ﬂow cytometer.
Pseudovirion neutralization assays
To conﬁrm the speciﬁcity of virus infection, Vero E6 cells were
infected with pseudovirions after preincubation with the anti-VSV G
monoclonal antibody I14, PUUV antisera, or HTNV antisera at 37 °C
for 30 min. They were then added to monolayers of Vero E6 cells in
a 96-well format. Cells were infected with pseudovirions at 37 °C for
1 h. After this incubation, 150 μL media was added to each infected
well and cells were incubated 24 h at 37 °C. Infection was analyzed
as noted above by lysing cells and determining levels of Renilla lucif-
erase expression. To test the ability of the pseudovirion assay to mea-
sure the neutralization capacity of experimental sera, 72 coded sera
samples were tested for neutralizing capability, including 25 pre-
bleed samples, 24 HTNV sera, and 23 PUUV sera. Pseudovirions
were pre-incubated with samples as per the neutralization protocol
(above). To determine IC50 values, pseudovirions were pre-treated
with serial dilutions of antisera ranging from 1:50 to 1:40,000,
depending on initial potency. The titer at which antisera neutralized
50% of luciferase signal was calculated from dose-response sigmoidal
curve analysis (Prism 4, GraphPad software, Inc.).
Plaque-reduction neutralization tests (PRNT)
Neutralization assays were performed as previously described
(Hooper et al., 2001). Heat-inactivated serum samples were diluted
and added at equal volume to ~75 plaque forming units (PFU) of han-
tavirus and 5% guinea pig complement. After an overnight incubation
at 4 °C, a plaque assay was performed using seven-day-old Vero E6
monolayers in six-well plates. HTNV PRNT was stained with neutral
red after one week and PUUV PRNT was stained after 9–10 days.
Plates were incubated at 37 °C and plaques were counted 2–3 days
after staining.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.virol.2011.08.012.
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